Premium
Atypical antipsychotics and anorexia nervosa: A review
Author(s) -
McKnight Rebecca F.,
Park Rebecca J.
Publication year - 2010
Publication title -
european eating disorders review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.511
H-Index - 67
eISSN - 1099-0968
pISSN - 1072-4133
DOI - 10.1002/erv.988
Subject(s) - olanzapine , quetiapine , anorexia nervosa , risperidone , atypical antipsychotic , psychiatry , eating disorders , psychology , anxiety , psychopathology , antipsychotic , clozapine , schizophrenia (object oriented programming) , medicine , clinical psychology
Background There is currently mixed opinion regarding the value of using atypical antipsychotics to treat anorexia nervosa (AN). Aims To evaluate the literature on the use of atypical antipsychotics in AN. Method A review of all studies and clinical guidelines published before September 2009 involving use of an atypical antipsychotic in patients with AN. Analysis is by narrative synthesis. Results Forty‐three publications or study protocols were found, including four randomized‐controlled trials, five open‐label trials and 26 case reports. The most studied drugs were olanzapine, quetiapine and risperidone. Atypical antipsychotics appear safe and there is some evidence of positive effects on depression, anxiety and core eating disordered psychopathology in patients with anorexia nervosa. Currently there is insufficient evidence to confirm atypical antipsychotics enhance weight gain in this setting. Conclusions Further high quality evidence is needed in this area in order to provide practical guidance to clinicians. However, the main challenge is to persuade adequate numbers of AN patients to participate in research trials. Copyright © 2010 John Wiley & Sons, Ltd and Eating Disorders Association.